E1A signaling to p53 involves the p19(ARF) tumor suppressor by de Stanchina,  E. et al.
 10.1101/gad.12.15.2434Access the most recent version at doi:
 1998 12: 2434-2442Genes Dev.
 
Elisa de Stanchina, Mila E. McCurrach, Frederique Zindy, et al.
 
tumor?suppressorARFE1A signaling to p53 involves the p19
 
 
References
 http://genesdev.cshlp.org/content/12/15/2434.full.html#related-urls
Article cited in: 
 
 http://genesdev.cshlp.org/content/12/15/2434.full.html#ref-list-1
This article cites 56 articles, 25 of which can be accessed free at:
service
Email alerting
 click heretop right corner of the article or
Receive free email alerts when new articles cite this article - sign up in the box at the
 http://genesdev.cshlp.org/subscriptions
 go to: Genes & DevelopmentTo subscribe to 
Cold Spring Harbor Laboratory Press
 Cold Spring Harbor Laboratory Press on March 23, 2012 - Published by genesdev.cshlp.orgDownloaded from 
E1A signaling to p53 involves the p19ARF
tumor suppressor
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The adenovirus E1A oncogene activates p53 through a signaling pathway involving the retinoblastoma protein
and the tumor suppressor p19ARF. The ability of E1A to induce p53 and its transcriptional targets is severely
compromised in ARF-null cells, which remain resistant to apoptosis following serum depletion or adriamycin
treatment. Reintroduction of p19ARF restores p53 accumulation and resensitizes ARF-null cells to apoptotic
signals. Therefore, p19ARF functions as part of a p53-dependent failsafe mechanism to counter uncontrolled
proliferation. Synergistic effects between the p19ARF and DNA damage pathways in inducing p53 may
contribute to E1A’s ability to enhance radio- and chemosensitivity.
[Key Words: E1A signaling; p53; p19ARF tumor suppressor]
Received June 23, 1998; accepted in revised form June 29, 1998.
Tumor-specific mutations identify genes essential for
normal growth control and reveal fundamental processes
involved in tumorigenesis. Similarly, viral oncoproteins
target cellular proteins critical for malignant transforma-
tion—often the same activities altered by spontaneous
mutation in cancer cells. For example, many DNA tu-
mor viruses encode proteins that bind and inactivate
both p53 and the retinoblastoma (Rb) protein, and inac-
tivation of both is essential for viral transformation
(Lane and Crawford 1979; Linzer and Levine 1979; De-
Caprio et al. 1988; Whyte et al. 1988a; Dyson et al. 1989;
Werness et al. 1990). Consistent with the relevance of
these interactions, p53 and Rb are frequently mutated in
human tumors (for review, see Greenblatt et al. 1994;
Weinberg 1995).
Although the high frequency of p53 mutations in hu-
man cancer implies a central role for p53 in tumorigen-
esis, the signals that trigger p53 in suppressing tumor
growth remain poorly defined. p53 is a sequence-specific
DNA-binding protein that promotes cell-cycle arrest or
apoptosis in response to a variety of cellular stresses (for
examples, see Kastan et al. 1991; Graeber et al. 1994;
Linke et al. 1996; for review, see Ko and Prives 1996;
Levine 1997). For example, p53 levels and activity in-
crease following DNA damage owing, in part, to de novo
phosphorylation and the accompanying conformational
changes (Shieh et al. 1997; Siliciano et al. 1997). Phos-
phorylation at serine-15 prevents p53’s interaction with
Mdm2 (Shieh et al. 1997), a protein that can down-regu-
late p53 via ubiquitin-mediated proteolysis (Haupt et al.
1997; Kubbutat et al. 1997). In principle, failure of p53 to
suppress proliferation following DNA damage might in-
directly promote tumor development by allowing the
growth and survival of cells with mutations (Livingstone
et al. 1992; Yin et al. 1992; Griffiths et al. 1997), but
whether this provides the primary driving force for p53
mutation in tumors is unclear.
Oncogenes can also induce p53, leading to increased
apoptosis or premature senescence (Lowe and Ruley
1993; Hermeking and Eick 1994; Wagner et al. 1994; Ser-
rano et al. 1997). For example, the adenovirus E1A on-
cogene induces p53 and promotes apoptosis in primary
cells (Debbas and White 1993; Lowe and Ruley 1993;
Querido et al. 1997; Samuelson and Lowe 1997), which is
reflected by E1A’s remarkable ability to enhance radio-
and chemosensitivity (Lowe et al. 1993). Although E1A
is a mitogenic oncogene, p53 acts to limit its oncogenic
potential. Thus, p53-deficient primary fibroblasts ex-
pressing E1A are resistant to apoptosis and become on-
cogenically transformed (Lowe et al. 1994b). Two E1A
domains act in concert to promote p53 accumulation
and apoptosis in primary cells; the first inactivates Rb,
whereas the second binds the p300/CBP transcriptional
coactivators (Samuelson and Lowe 1997). Interestingly,
the integrity of both domains is required for E1A’s on-
cogenic potential (Whyte et al. 1988b, 1989). The ability
of E1A to activate p53 is not unique, as c-Myc activates
p53 to promote apoptosis (Hermeking and Eick 1994;
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Wagner et al. 1994) and oncogenic ras induces p53 lead-
ing to premature senescence (Serrano et al. 1997). How
oncogenic signals activate p53 is not known, although it
is conceivable that they induce p53 by inadvertently
damaging DNA. Nevertheless, the general involvement
of p53 in the cellular response to oncogenes raises the
possibility that these stimuli are fundamental to p53’s
tumor suppressor activity.
The INK4a/ARF locus is second only to p53 in the
frequency of its disruption in human cancer (for re-
view, see Haber 1997). This locus encodes p16INK4a,
a cyclin-dependent kinase inhibitor (CDKI) that acts
upstream of Rb to promote cell-cycle arrest (Serrano
et al. 1993). Although compelling evidence indicates
that p16INK4a is an important tumor suppressor, the
INK4a/ARF locus encodes a second protein translated
in an alternate reading frame, designated p19ARF (Quelle
et al. 1995). p19ARF and p16INK4a are often codeleted
in tumor cells, but mice lacking p19ARF alone are highly
cancer prone (Kamijo et al. 1997; for review, see Haber
1997). p19ARF promotes cell-cycle arrest (Quelle et
al. 1995), whereas ARF-null primary mouse embryo
fibroblasts (MEFs) do not undergo replicative senes-
cence and are transformed by oncogenic ras alone (Ka-
mijo et al. 1997). Thus, ARF is a bona fide tumor sup-
pressor.
p19ARF may function in a genetic and biochemical
pathway that involves p53. At the organismal level, the
consequences of deleting p53 and ARF are remarkably
similar (Donehower et al. 1992; Kamijo et al. 1997). In
either case, the mutant mouse develops normally but is
highly predisposed to malignant tumors of a similar
overall pattern and latency. At the cellular level, en-
forced expression of p19ARF can induce cell-cycle arrest
in cells harboring wild-type but not mutant p53 (Kamijo
et al. 1997). In turn, p19ARF can physically associate with
p53 itself and/or Mdm2 to alter p53 levels and activity
(Kamijo et al. 1998; Pomerantz et al. 1998; Zhang et al.
1998). Nevertheless, ARF is not required for the p53 re-
sponse following DNA damage, as radiation induces G1
arrest in ARF-deficient fibroblasts and apoptosis in ARF-
deficient thymocytes (Kamijo et al. 1997, 1998). Thus, an
understanding of the signals that activate p19ARF may
help to explain its role as a tumor suppressor as well as
that of p53.
In this study we compared the mechanism whereby
DNA damaging agents and the E1A oncogene activate
p53. We demonstrate that E1A activates p53 through a
fundamentally different mechanism than DNA damage,
which is dependent on the presence of p19ARF. Further-
more, simultaneous activation of p53 through oncogenes
and DNA damage synergize to promote apoptosis and
thereby enhance radio- and chemosensitivity. These data
imply that p19ARF acts to suppress tumor growth in re-
sponse to hyperproliferative signals. Conversely, as
p19ARF mediates activation of p53 by an oncogene and is
frequently lost in human tumors, these data strongly
support the view that p53’s tumor suppressor activity
can arise from its ability to eliminate oncogene-express-
ing cells.
Results
E1A and DNA damage induce p53 through distinct
mechanisms
The E1A oncogene induces p53 through a mechanism
involving inactivation of Rb gene product, and up-regu-
lation of p53 correlates with the ability of E1A to pro-
mote apoptosis (Lowe and Ruley 1993; Lowe et al. 1994b;
Samuelson and Lowe 1997). DNA damage produced by
radiation and certain cytotoxic drugs also activates p53,
at least in part, through a kinase that phosphorylates p53
on serine-15 (Shieh et al. 1997; Siliciano et al. 1997). To
determine whether DNA damage and E1A induce p53
through similar mechanisms, we examined the phos-
phorylation status of p53 on serine-15 in cells expressing
or lacking E1A. E1A was introduced into normal diploid
human fibroblasts (IMR90 cells) by retroviral-mediated
gene transfer. After a 3-day drug selection to eliminate
uninfected cells, p53 levels and phosphorylation status
were assessed by Western blot analysis using antibodies
that recognize total p53 or only that fraction phosphory-
lated on serine-15 (Shieh et al. 1997; Siliciano et al.
1997). For comparison, IMR90 cells were treated with
ionizing radiation or with the calpain/proteosome in-
hibitor LLnL, both of which are also known to stabilize
p53 (Maki et al. 1996). Total p53 was examined by West-
ern blotting; alternatively, p53 was immunoprecipitated
and scored for the presence of serine-15 phosphate using
antibodies that detect this epitope.
As expected, ionizing radiation produced a large in-
crease in p53 protein (Fig. 1A, lane 2) accompanied by
p53 phosphorylation on serine 15 (Fig. 1B, lane 2). LLnL
also induced p53 but without serine-15 phosphorylation
(Fig. 1, A, lane 3, and B, lane 1). E1A produced even
greater increases in p53 levels (Fig. 1A, lane 4) without
detectable phosphorylation of p53 on serine 15 (Fig. 1B,
lane 3). However, E1A did not inhibit p53 phosphoryla-
tion on serine-15, as g-irradiation of cells expressing E1A
produced little, if any, additional increase in p53 protein
(Fig. 1A, lane 5) but led to a marked increase in anti-
phosphoserine-15 reactivity (Fig. 1B, lane 5). Induction of
p53 in the absence of serine-15 phosphorylation argues
that E1A does not produce DNA damage indirectly but,
rather, suggests that E1A and ionizing radiation activate
p53 through distinct mechanisms.
E1A induces p19ARF through domains required for p53
accumulation and apoptosis
Enforced expression of p19ARF stabilizes p53 and arrests
proliferation in a p53-dependent manner, yet ARF is not
required for radiation-induced cell-cycle arrest or apop-
tosis (Kamijo et al. 1997; Pomerantz et al. 1998; Zhang et
al. 1998). The fact that E1A also stabilizes p53 through a
DNA damage-independent mechanism is consistent
with the possibility that E1A acts through p19ARF to
induce p53. E1A or various E1A mutants were intro-
duced into primary MEFs, and p19ARF expression was
monitored 3 days later. E1A caused a dramatic induction
of p19ARF, correlating with p53 accumulation (Fig. 2, A
E1A activates p53 via p19ARF
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and B, cf. lanes 2 and 1). A similar increase was also
observed in ARF mRNA expression, indicating that E1A
was affecting ARF transcription or message stability (Fig.
2B, cf. lanes 2 and 1). As demonstrated previously (Ka-
mijo et al. 1997), ARF is constitutively upregulated in
p53−/− MEFs (Fig. 2B, lane 5), suggesting the presence of
a negative feedback loop. However, E1A still induced
p19ARF expression in p53-deficient cells (two- to three-
fold), implying that p53 is not required for p19ARF up-
regulation by E1A (Fig. 2B, lane 6).
E1A associates with a series of cellular proteins, in-
cluding Rb, the Rb-related proteins p107 and p130, and
the transcriptional coactivators p300 and CBP (for re-
view, see Flint and Shenk 1997). E1A mutants unable to
bind either p300/CBP (E1A DN) or the Rb-family pro-
teins (E1A DCR2) were impaired in their ability to in-
duce p19ARF and p53 (Fig. 2A, lanes 3,4), implying that
E1A’s ability to bind both sets of cellular proteins is re-
quired for maximal p19ARF accumulation. In agreement,
p19ARF protein induction was restored in cells coinfected
with both E1A mutants (data not shown). p19ARF levels
were slightly elevated in Rb-deficient MEFs (Fig. 2A,
lane 5) although this difference was more pronounced in
later passage MEFs (data not shown; see also Zindy et al.
1998). Importantly, p19ARF levels were further increased
by expression of E1A (Fig. 2A, lane 6) or, in contrast to
normal cells, the E1A DCR2 mutant (Fig. 2A, cf. lanes 4
and 8). However, p19ARF was not elevated in p107- and
p130-deficient MEFs, nor was it induced by E1A DCR2
(data not shown). Thus, among the Rb-family proteins
that bind E1A, the recognized ability of E1A to inactivate
Rb solely contributes to p19ARF accumulation. These
data demonstrate that at least two E1A functions con-
tribute to p19ARF induction: inactivation of Rb and, pos-
sibly, binding to p300/CBP. Notably, these are the same
domains of E1A that are necessary for its ability to in-
duce p53 and promote apoptosis (Samuelson and Lowe
1997).
ARF promotes p53 accumulation in response to E1A
p53 activation is typically accompanied by increased ex-
pression of its transcriptional targets, including p21 and
Mdm2. p21 is a CDKI involved in p53-dependent cell-
cycle arrest (El Deiry et al. 1993; Harper et al. 1993;
Xiong et al. 1993). Mdm2 acts in a negative feedback loop
to down-regulate p53 and is expressed from two promot-
ers, one of which is regulated by p53 (Barak et al. 1993,
Figure 1. E1A induces p53 in the absence of phosphorylation
on serine-15. IMR90 fibroblasts were infected with control
(IMR) or E1A-expressing (IMR/E1A) retroviruses. Extracts were
prepared from untreated cells (c), or from cells treated 3 hr ear-
lier with 7 Gy g radiation (g) or 2 hr earlier with 50 µM LLnL
(LL). (A) p53 levels were determined by Western blot analysis
using pAb 1801 and DO1. Equal loading of the gel was con-
firmed by stripping the blot and reprobing with anti-b-actin
antiserum. (B) p53 was immunoprecipitated from extracts cor-
responding to 100 µg (IMR) or 35 µg (IMR/E1A) total protein
using pAb 1801, and Western blots were probed with antibodies
specific for p53 phosphoserine-15 (ap53-P–Ser-15).
Figure 2. E1A induces p19ARF and p53 through a similar
mechanism. (A) Early passage (about three to four) wild-type and
Rb−/− MEFs from littermates embryos were infected with ret-
roviruses expressing full-length E1A or E1A mutants unable to
bind p300/CBP (DN) or the Rb-related proteins (DCR2). An
empty retroviral vector was used as a control (vector). Immu-
noblotting was performed using polyclonal antibodies against
p19ARF or p53. Using this procedure, each E1A mutant is effi-
ciently expressed at comparable levels (Samuelson et al. 1997).
(B) Wild-type (WT), ARF-null (ARF−/−), and p53-null (p53−/−)
MEFs were infected with a control vector (V) or a retrovirus
expressing full-length E1A (E). Lysates were derived from whole
populations passaged minimally in culture (<1 week) and ana-
lyzed for ARF protein (top) or mRNA (middle) expression by
Western or Northern blotting, respectively. Northern blots
were rehybridized using a probe to the 18S rRNA to confirm
equal loading (bottom).
de Stanchina et al.
2436 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on March 23, 2012 - Published by genesdev.cshlp.orgDownloaded from 
1994; Wu et al. 1993). To determine whether ARF is
required for p53 induction by E1A, the expression of p53,
p21, and Mdm2 were examined in wild-type, ARF−/−,
and p53−/− MEFs. In wild-type MEFs, E1A increased p53
protein expression, which was accompanied by accumu-
lation of p21 and several forms of Mdm2 (Fig. 3A, lane 2).
Induction of p21 and Mdm2 was p53-dependent, as nei-
ther protein was induced by E1A in p53-deficient cells
(Fig. 3A, lane 6). Remarkably, expression of equivalent
levels of E1A did not induce p53 in ARF-deficient cells,
nor affect its targets p21 and Mdm2 (Fig. 3A, lane 4). Of
note, wild-type and ARF−/− MEFs infected with a control
vector displayed similar p53 levels, indicating that
p19ARF loss does not markedly affect basal p53 expres-
sion (compare lanes 1 and 3). Therefore, ARF facilitates
the up-regulation of p53 protein and its associated tran-
scriptional activity following expression of E1A.
When activated by DNA damage, Mdm2 is induced as
part of a negative feedback loop that facilitates p53 deg-
radation. However, wild-type MEFs expressing E1A ac-
cumulate p53 despite a large increase in Mdm2 levels
(see Fig. 3A, lane 2). We examined the ability of Mdm2 to
associate with p53 in MEFs expressing E1A by use of
sequential immunoprecipitation and Western blotting.
Despite the fact that wild-type MEFs expressing E1A dis-
played an ∼10-fold increase in p53 and Mdm2 levels as
compared to their ARF-deficient counterparts, the abso-
lute amount of Mdm2 bound to p53 was comparable in
both cell types (Fig. 3B, cf. p53, lanes 2 and 4). Thus, p53
associates poorly with Mdm2 in wild-type cells express-
ing E1A. This implies that p19ARF, either directly or in-
directly, contributes to p53 accumulation by preventing
Mdm2-mediated degradation of p53 (Pomerantz et al.
1998; Zhang et al. 1998).
Inactivation of ARF attenuates apoptosis
E1A sensitizes primary fibroblasts to apoptosis induced
by diverse stimuli, including serum depletion and treat-
ment with chemotherapeutic drugs. The fact that ARF-
deficient cells are unable to induce p53 in response to
E1A suggests that ARF−/− MEFs expressing E1A might be
resistant to apoptosis. Consistent with this possibility,
the ability of Rb deficiency to trigger apoptosis was at-
tenuated in developing mouse lenses disrupted for both
ARF and INK4a (Pomerantz et al. 1998). Therefore, we
compared the sensitivity of various virus-infected popu-
lations to cell death following serum withdrawal and
treatment with adriamycin, a chemotherapeutic drug
that produces double-stranded DNA breaks (Ross and
Bradley 1981) and induces p53-dependent apoptosis in
this setting. Two criteria were used to monitor apopto-
sis: annexin V staining followed by flow cytometry to
assay membrane changes, and DAPI staining followed by
fluorescence microscopy to visualize the characteristic
chromatin condensation in apoptotic cells.
Concordant with previous results, wild-type MEFs ex-
pressing E1A lost viability following serum depletion or
adriamycin treatment, whereas p53−/− MEFs expressing
E1A did not (Fig. 4A,B). ARF−/− MEFs were significantly
more resistant to E1A-induced apoptotic signals as com-
pared to their wild-type counterparts but were somewhat
more sensitive than cells lacking p53. In all cases, cell
death was due to apoptosis, as measured by annexin V
binding as well as chromatin condensation (Fig. 4C). Un-
infected MEFs of all genotypes remained viable follow-
ing serum depletion or adriamycin treatment at these
doses, indicating that E1A was required for apoptosis un-
der these conditions (data not shown). Therefore, p19ARF
contributes to p53’s apoptotic potential in cells express-
ing E1A. However, the fact that p53 loss is more protec-
tive than ARF loss implies that some apoptotic signals
address p53 through a p19ARF-independent pathway. For
example, adriamycin might also exert some of its effects
through the DNA damage pathway (see below).
If ARF loss protects cells from apoptosis in a p53-de-
pendent manner, a clear prediction is that reintroduction
of ARF into E1A-expressing cells containing wild-type
p53 should resensitize them to the effects of serum dep-
rivation and adriamycin. Conversely, cells lacking p53
should be unaffected by ARF. Hemagluttinin (HA)-
Figure 3. p19ARF mediates p53 induction by E1A and interferes
with the p53/Mdm2 interaction. Wild-type (WT), ARF-null
(ARF−/−) and p53-null (p53−/−) cell populations harboring a con-
trol vector (V) or expressing E1A (E) were prepared by retroviral
gene transfer. Protein expression was analyzed in whole cell
populations passaged minimally in culture (<1 week). (A) p53
protein levels along with the levels of its transcriptional targets
p21 and Mdm2 were determined by immunoblotting. (B)
Mdm2/p53 complexes were examined in wild-type and ARF-
null populations expressing E1A by immunoprecipitation with
monoclonal antibodies directed against p53 (P) or Mdm2 (M),
followed by immunoblotting with a polyclonal rabbit antibody
against p53. The blots were then reprobed using the same mono-
clonal antibody against Mdm2. Note that the p53 blot was over-
exposed to allow visualization of the amount associated with
Mdm2.
E1A activates p53 via p19ARF
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tagged ARF was introduced by retroviral gene transfer
into wild-type, ARF−/−, and p53−/− MEFs expressing E1A.
Cells were infected at high multiplicity to bypass a need
for drug selection. Exogenous p19ARF expression caused
a 5- to 10-fold increase in p53 expression in both wild-
type and ARF−/− MEFs expressing E1A (Fig. 5A), consis-
tent with previous results (Kamijo et al. 1997, 1998).
E1A-expressing wild-type MEFs infected with a control
vector did not undergo apoptosis in high serum condi-
tions but upon transfer to low serum conditions, under-
went similar levels of apoptosis as uninfected E1A-ex-
pressing MEFs (Fig. 5B). As shown above (see Fig. 4), vec-
tor-infected cells lacking ARF or p53 were resistant to
apoptosis when transferred to serum-depleted medium
(Fig. 5B). Following infection with ARF retrovirus, both
wild-type and ARF−/− MEFs expressing E1A displayed a
modest increase in apoptosis when maintained in serum
and underwent massive apoptosis upon serum depletion.
Importantly, the same levels of exogenous p19ARF had
little effect on p53−/− MEFs (Fig. 5B). Hence, depending
upon the growth conditions, p19ARF can act upstream of
p53 to induce either cell cycle arrest (Kamijo et al. 1997)
or apoptosis. The fact that restoration of ARF function
can resensitize ARF−/− MEFs to the combined effects of
E1A and low serum provides compelling evidence that
attenuation of apoptosis in ARF−/− cells is a direct con-
sequence of ARF loss and not due to additional genetic
changes.
Synergy between p19ARF-dependent and -independent
pathways targeting p53
Because DNA damage and E1A can activate p53 through
Figure 5. Reintroduction of p19ARF restores apoptosis. Control
and E1A-expressing populations derived from wild-type (WT),
ARF-null (ARF−/−) and p53-null (p53−/−) populations were in-
fected with retroviruses expressing lacZ or an HA-tagged ARF
cDNA (Quelle et al. 1995). Thirty-six hours later, the resulting
cell populations were analyzed for p53 and exogenous p19ARF
protein expression or treated with apoptotic stimuli. (A) Immu-
noblotting of infected populations using a monoclonal antibody
recognizing the HA epitope fused to p19ARF or a polyclonal an-
tibody directed against p53. The arrow denotes the migration of
HA-tagged p19ARF. (B) The indicated cell populations were
placed in 10% (shaded bars) or 0.1% (solid bars) serum for 24 hr
and cell viability was measured by trypan blue exclusion. The
values represent the mean and S.D. of at least three separate
infections.
Figure 4. E1A-expressing cells lacking ARF
are defective in apoptosis. Wild-type (d), ARF-
null (m), and p53-null (j) early passage MEFs
were infected with control retroviruses (not
shown) or retroviruses expressing E1A. Within
a week of gene transfer, the resulting cell
populations were examined for cell death at
various times following serum depletion (A) or
24 hr after treatment with the indicated doses
of adriamycin (B). Cell viability was assessed
by trypan blue exclusion. Each point repre-
sents the mean±S.D. from at least three sepa-
rate experiments. Fibroblasts of all genotypes
infected with a control vector retained viabil-
ity (>90%) following serum depletion or adria-
mycin treatment (data not shown). (C) Wild-
type (WT), ARF-null (ARF−/−) and p53-null
(p53−/−) MEFs expressing E1A were examined
for apoptosis 18 hr after transfer to 0.1% serum
conditions. Annexin V binds phosphotidylser-
ine. Apoptotic changes in membrane biochem-
istry lead to increased concentration of phos-
photidylserine on the outer plasma membrane,
where it becomes accessible to annexin V (An-
dree et al. 1990). Propidium iodide fluorescently stains late apoptotic cells that have lost membrane integrity. Shown are representative
dot plots from two-color flow cytometry: (Bottom left quadrant) Viable; (bottom right quadrant) early apoptotic; (top right quadrant)
late apoptotic. DAPI staining allows visualization of the chromatin condensation characteristic of apoptotic cells. Note that there was
little apoptosis in E1A-expressing populations in 10% serum nor in vector-only control populations in 0.1% serum (data not shown).
de Stanchina et al.
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distinct mechanisms, they might act synergistically to
enhance cellular chemo- or radiosensitivity. Consistent
with this possibility, enforced expression of p19ARF
caused a marked increase in apoptosis induced by adria-
mycin when expressed in either wild-type or ARF−/−
MEFs expressing E1A (Fig. 6A). Similar results were ob-
tained following treatment of the cells with ionizing ra-
diation (Fig. 6B). Importantly, the enhanced chemosen-
sitivity produced by enforced p19ARF expression required
both E1A and a cytotoxic insult. Hence, wild-type MEFs
lacking E1A did not undergo apoptosis following adria-
mycin treatment and remained insensitive to low doses
of the drug upon enforced expression of p19ARF (Fig. 6A,
squares). ARF−/− cells expressing E1A were relatively re-
sistant to drug-induced apoptosis (see also Fig. 4) but
were resensitized when ARF was reintroduced (Fig. 6A,
triangles). Importantly, introduction of ARF into wild-
type cells expressing E1A also enhanced apoptosis in re-
sponse to low doses of adriamycin (Fig. 6A, circles) or
ionizing radiation (Fig. 6B), demonstrating that activa-
tion of the ARF–p53 pathway promotes both chemo- and
radiosensitivity in the face of an oncogenic signal.
Discussion
Oncogenic signaling through the ARF–p53 pathway
A variety of cellular stresses activate p53, including
DNA damage, hypoxia, and expression of mitogenic on-
cogenes (for review, see Ko and Prives 1996; Levine
1997). Following DNA damage, p53 becomes phosphory-
lated by kinases such as DNA–PK or ATM, leading to
changes in p53 conformation and activity. In contrast,
the E1A oncogene activates p53 through a fundamen-
tally different mechanism, mediated largely by the tu-
mor suppressor p19ARF. Importantly, the DNA damage
and E1A signaling pathways act in parallel: E1A does not
produce p53 phosphorylation at serine-15 and DNA
damage activates p53 independently of p19ARF (Kamijo
et al. 1997). Moreover, p53 is phosphorylated on serine-
15 following irradiation of ARF-deficient cells (data not
shown). Therefore, these data provide a clear example of
how p53 integrates upstream signaling pathways ema-
nating from diverse stimuli (Fig. 7).
Activation of p53, in turn, can produce several cellular
responses, including transient cell-cycle arrest, senes-
cence or apoptosis. Each signaling pathway to p53 may
produce subtle differences in p53 activity or function,
and perhaps the diversity achieved by a combination of
Figure 6. Synergy between p19ARF-dependent and -indepen-
dent pathways targeting p53. (A) lacZ (solid symbols)- and HA–
ARF (open symbols)-expressing cell populations were treated
with the indicated doses of adriamycin, and cell viability was
determined 24 hr later by trypan blue exclusion. The cell popu-
lations were as follows: Wild-type MEFs lacking E1A (squares);
wild-type MEFs expressing E1A (circles); ARF−/− MEFs express-
ing E1A (triangles). Note that ARF−/− and p53−/− MEFs lacking
E1A, as well as p53-deficient MEFs expressing E1A, remained
viable in adriamycin whether or not they expressed HA–p19ARF
(data not shown). (B) lacZ (V, shaded bars) and HA–p19ARF (p19,
solid bars) expressing cell populations were treated with 7 Gy
ionizing radiation and cell viability was determined 24 hr later
by trypan blue exclusion. The values represent the mean and
S.D. of at least three separate populations. MEFs not expressing
E1A were resistant to apoptosis under these conditions (data not
shown; see also Lowe et al. 1993).
Figure 7. Oncogenes and DNA damage activate p53 through
distinct mechanisms. p19ARF acts as an intermediary in p53
activation by mitogenic oncogenes such as E1A and myc. In
contrast, activation of p53 following DNA damage involves de
novo phosphorylation of p53 on serine-15 (and other residues)
by kinases such as the DNA-dependent protein kinase (DNA–
PK) or the product of the ataxia-telangiectasia gene (ATM)
(Shieh et al. 1997; Siliciano et al. 1997). Activation of p53 by
oncogenes does not involve phosphorylation on serine-15, and
both serine-15 phosphorylation (not shown) and p53 activation
(Kamijo et al. 1997) following DNA damage are unimpaired in
the absence of ARF. Therefore, the two upstream signaling path-
ways to p53 are fundamentally distinct.
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these signals accounts for the complex biology of p53.
For example, simultaneous activation of p53 by p19ARF
and DNA damage synergize to promote apoptosis in the
presence of the E1A oncogene (Fig. 6; see also Lowe et al.
1993; Samuelson and Lowe 1997). If similar processes
occur in human cancer, therapeutic strategies to exploit
p19ARF activation may enhance the radiosensitivity or
chemosensitivity of p53-expressing tumors.
Like p53, the outcome of p19ARF activation is depen-
dent on cellular context. For example, enforced ARF ex-
pression in MEFs induces cell cycle arrest, but cells over-
expressing p19ARF, together with E1A or Myc (Zindy et
al. 1998), undergo apoptosis, which is potentiated by
withdrawal of serum survival factors (Evan et al. 1992;
Lowe and Ruley 1993; Lowe et al. 1994b). ARF-null
MEFs are resistant to both E1A- and Myc-induced apop-
tosis, bypassing the p53-dependent fail-safe mechanism
that normally protects them from these oncogenic sig-
nals, and thereby enabling E1A and Myc to function as
pure growth promoters. Myc’s action as an ‘‘immortal-
izing gene’’ depends in part on its ability to dismantle
the ARF–p53 pathway by selecting for surviving cells
that have lost either gene (Zindy et al. 1998). In turn,
ARF-null MEFs do not undergo replicative senescence
and can be transformed by oncogenic ras alone (Kamijo
et al. 1997). We suspect that E1A’s immortalizing activ-
ity involves similar mechanisms.
Also like p53, ARF has no overt role in normal cell
cycle control or development; hence, the physiologic cir-
cumstances in which it would become activated to in-
hibit proliferation or suppress tumor growth were not
obvious. Studies here with E1A mutants suggest that
p19ARF can be activated to suppress proliferation by the
E1A oncogene through mechanisms that correlate with
its binding to both p300/CBP and Rb. These same func-
tions are required for E1A to induce p53 and to promote
apoptosis in primary fibroblasts (Samuelson and Lowe
1997) and, remarkably, are also required for E1A’s trans-
forming potential (Whyte et al. 1988b, 1989). Loss of Rb
contributes to ARF induction consistent with the possi-
bility that ARF is an E2F-responsive gene (DeGregori et
al. 1997). Enforced expression of E2F-1 induces p19ARF,
and conversely, ARF-null cells are resistant to E2F-1-
induced apoptosis (Zindy et al. 1998). Consequently,
p19ARF function, like p53, depends upon the muta-
tional status of Rb, and upon both c-myc and ras proto-
oncogene activities. Irrespective of the precise out-
come, ARF mutations compromise p53 activation and
reduce its ability to counter uncontrolled prolifera-
tion.
The data presented here provide additional insights
into p53’s role in tumor suppression. The predominant
view of p53 action centers around its ability to function
in the cellular response to DNA damage. Although this
stimulus is undoubtedly important for p53’s tumor sup-
pressor activity and may contribute to the outcome of
cancer therapy (Lowe et al. 1993, 1994a), p53 activation
in response to oncogenes provides an alternative pres-
sure to mutate p53 during tumorigenesis (Lowe and Ru-
ley 1993; Lowe et al. 1994b; Symonds et al. 1994). In this
view, p53 normally acts to limit the consequences of
uncontrolled mitogenesis by promoting cell-cycle arrest
or apoptosis, while its loss allows proliferation to con-
tinue unabated. The fact that disruption of the ARF-p53
pathway occurs in the majority of human cancers under-
scores its global importance in suppressing proliferation
of oncogene-expressing cells.
Materials and methods
Cells and cell culture
IMR90 fibroblasts (early–mid passages) expressed the ecotropic
retrovirus receptor to allow infection with murine retroviruses
(Serrano et al. 1997). Primary MEFs derived from wild-type,
p53−/− (Jacks et al. 1994), and ARF−/− (Kamijo et al. 1997) day
13.5 embryos were prepared as described previously (Serrano et
al. 1997). All cultures were maintained in Dulbecco’s modified
Eagle’s medium (DMEM; GIBCO) supplemented with 10% fetal
bovine serum (FBS; Sigma) and 1% penicillin G/streptomycin
sulfate (Sigma). To induce DNA damage, cells were either irra-
diated with 7 Gy ionizing radiation using a J.L. Shepherd Mark
I irradiator with a 137Cs source or treated with 0.1–0.5 µg/ml
adriamycin. To induce p53 independently of DNA damage, cells
were treated for 2 hr with 50 µM LLnL (Sigma).
Retroviral vectors and infection
For most experiments, high-titer ecotropic retroviruses were
generated by transient transfection using the Phoenix retrovirus
packaging system (G. Nolan, Stanford University, CA) as de-
scribed previously (Serrano et al. 1997). Virus supernatants were
used to infect either IMR90 fibroblasts or early-passage MEFs
(øpassage 5), and pure populations of E1A-expressing cells were
isolated by selection for 2 days in the presence of 2 µg/ml pu-
romycin. Infection was typically between 70% and 90% of cells
as judged using a control virus expressing b-galactosidase (not
shown). For ectopic expression of p19ARF, a protocol designed to
achieve nearly complete infection of cells (Zindy et al. 1998)
was used. Retroviral vectors were as follows: LPC, control vec-
tor expressing puromycin phosphotransferase (puro); LPC-12S, a
12S E1A cDNA in LPC (McCurrach et al. 1997); LPC-12S.DN
and LPC-12S.DCR2, E1A mutants that fail to associate with
p300/CBP or the Rb-related proteins, respectively (Samuelson
and Lowe 1997). The retroviral vector encoding HA–p19ARF co-
expressed a CD8 cell surface marker (Quelle et al. 1995). pBa-
bePuro–lacZ (a gift of J. Morgenstern, Millenium Pharmaceuti-
cal, Cambridge, MA) was used to monitor infection efficiencies
and, in some experiments, as a control vector.
Gene expression
Analysis of p53 phosphorylation on serine-15 was performed
exactly as described (Shieh et al. 1997). p53 levels were deter-
mined by Western blots using PAb1801 and DO1. p53 immu-
noprecipitations were performed using pAb 1801 followed by
immunoblotting with ap53-P–Ser-15 to identify p53 proteins
phosphorylated on serine-15. Western blots to detect p19ARF
were performed using antibodies to the carboxyl terminus as
described (Kamijo et al. 1998); HA-tagged p19ARF was detected
using mAb 12CA5 (1:5000 dilution). All other Western blots
were carried out as described previously with minor modifica-
tions (Serrano et al. 1997). Whole-cell lysates were derived by
lysing cell pellets in SDS sample buffer (60 mM Tris-HCl at pH
6.8, 10% glycerol, 2% SDS, 5% 2-mercaptoethanol). Samples
corresponding to 30 µg of protein (Bio-Rad protein assay) were
de Stanchina et al.
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separated on SDS-PAGE gels and transferred to Immobilon-P
membranes (Millipore). p53 was detected using polyclonal an-
tibody CM5 (1:8000 dilution) (a gift of Peter Hall, Dundee Uni-
versity, UK); Mdm2 using mAb 2A10 (provided by G. Zambetti,
St. Jude Children’s Research Hospital); p21 using polyclonal an-
tibody C-19 (1: 500 dilution) (Santa Cruz), and E1A using mAb
M58 (Harlow et al. 1985). Proteins were visualized by ECL (Am-
ersham) and equal sample loading was confirmed by India Ink or
Ponseau S staining of the membrane.
For p53/Mdm2 immunoprecipitations, cell pellets were dis-
rupted in ice-cold NP-40 lysis buffer (50 mM Tris-HCl at pH 8,
5 mM EDTA, 150 mM NaCl, 0.5% NP-40, 1 mM PMSF, 0.4 U/ml
aprotinin, 10 mM b-glycerophosphate, 1 mM NaF, 0.1 mM
Na3VO4) on ice for 1 hr. Cleared lysates were incubated for 2 hr
at 4°C with two monoclonal antibodies directed against p53
(pAb 421 and pAb 248) or Mdm2 (2A10), plus 10 mg/ml BSA.
Complexes precipitated with protein A–Sepharose (Amersham)
were washed three times with ice-cold NP-40 lysis buffer. Im-
munoprecipitates were separated on 7.5% SDS–polyacrylamide
gels and transferred to nitrocellulose. Mdm2 was detected by
immunoblotting using the same antibody, whereas p53 was de-
tected with CM5 polyclonal antibody as described above.
For Northern blots, total RNA was extracted from cells using
RNAzolB (Cinna/Biotecx) ∼1 week postinfection and 30 µg was
loaded per lane. Following agarose gel electrophoresis and trans-
fer to Hybond membranes (Amersham), blots were hybridized
with a 32P-labeled probe specific for INK4a exon 1b [the portion
of the INK4a/ARF locus unique to ARF (Quelle et al. 1995)]. A
probe specific for 18S rRNA was used to confirm equal loading.
Cell viability and apoptosis
Cells were distributed into 12-well plates (105 cells/22-mm
well) 12–24 hr prior to serum withdrawal, radiation, or drug
treatment. Adherent and nonadherent cells were pooled 24 hr
after treatment with g-radiation, adriamycin, or 0.1% FBS and
analyzed for viability by trypan blue exclusion; ù200 cells were
scored for each point. Apoptotic cell death was confirmed by
staining with DAPI or FITC–annexin V. Cells (∼1 × 105) were
fixed in 5% paraformaldehyde (Mallinckrodt) and DNA was
stained with DAPI (1 µg/ml). Images were digitized using a
fluorescence microscope coupled to a Photometrics PXL CCD
camera (Photometrics Ltd.). For annexin staining, cells were
incubated in DMEM with 0.1% FBS for 18 hr, after which ad-
herent and nonadherent cells were pooled. Staining with FITC–
annexin V and PI were performed according to the manufactur-
er’s instructions (BioWhitaker) and the cells were analyzed by
two-color flow cytometry.
Acknowledgments
We thank Y. Taya for the generous gift of immunopurified an-
tibodies directed against phosphoserine-15 p53 and N. Dyson
for p107- and p130-deficient MEFs. We also thank Maria Coro-
nesi and Esther Van de Kamp for technical assistance. E.S. is
supported by the Italian Ph.D. program and thanks Dr. G. Bi-
amonti and Professor A. Galizzi for support; G.F. is a Tularik
postdoctoral fellow; A.V.S. is supported by an Army Breast Can-
cer Research fellowship; S.W.L. is supported by a Kimmel Schol-
arship Award. This work was funded in part by American Leba-
nese Syrian Associated Charities of St. Jude Children’s Research
Hospital, and by grants CA58316 (C.P.); CA56819, CA71907
(M.F.R.), and CA13106 (S.W.L) from the National Institutes of
Health.
The publication costs of this article were defrayed in part by
payment of page charges. This article must therefore be hereby
marked ‘‘advertisement’’ in accordance with 18 USC section
1734 solely to indicate this fact.
References
Andree, H.A., C.P. Reutelingsperger, R. Hauptmann, H.C.
Hemker, W.T. Hermens, and G.M. Willems. 1990. Binding of
vascular anticoagulant alpha (VAC alpha) to planar phospho-
lipid bilayers. J. Biol. Chem. 265: 4923–4928.
Barak, Y., T. Juven, R. Haffner, and M. Oren. 1993. mdm2 ex-
pression is induced by wild-type p53 activity. EMBO J.
12: 461–468.
Barak, Y., E. Gottlieb, T. Juvengershon, and M. Oren. 1994.
Regulation of mdm2 expression by p53: Alternative promot-
ers produce transcripts with nonidentical translation poten-
tial. Genes & Dev. 8: 1739–1749.
Debbas, M. and E. White. 1993. Wild-type p53 mediates apop-
tosis by E1A, which is inhibited by E1B. Genes & Dev.
7: 546–554.
DeCaprio, J.A., J.W. Ludlow, D. Lynch, Y. Furukawa, J. Griffin,
H. Piwnica-Worms, C.M. Huang, and D.M. Livingstone.
1988. SV40 large T antigen forms a specific complex with the
product of the retinoblastoma susceptibility gene. Cell
54: 275–283.
DeGregori, J., G. Leone, A. Miron, L. Jakoi, and J.R. Nevins.
1997. Distinct roles for E2F proteins in cell growth control
and apoptosis. Proc. Natl. Acad. Sci. 94: 7245–7250.
Donehower, L.A., M. Harvey, B.L. Slagle, M.J. McArthur, C.A.
Montgomery, J.A. Butel, and A. Bradley. 1992. Mice defi-
cient for p53 are developmentally normal but susceptible to
spontaneous tumours. Nature 356: 215–220.
Dyson, N., P.M. Howley, K. Munger, and E. Harlow. 1989. The
human papilloma virus-16 E7 oncoprotein is able to bind to
the retinoblastoma gene product. Science 243: 934–937.
El Deiry, W.S., T. Tokino, V.E. Velculescu, D.B. Levy, R. Par-
sons, J.M. Trent, D. Lin, W.E. Mercer, K.W. Kinzler, and B.
Vogelstein. 1993. WAF1, a potential mediator of p53 tumor
suppression. Cell 75: 817–825.
Evan, G.I., A.H. Wyllie, C.S. Gilbert, T.D. Littlewood, H. Land,
M. Brooks, C. Waters, L.Z. Penn, and D.C. Hancock. 1992.
Induction of apoptosis in fibroblasts by c-myc protein. Cell
69: 119–128.
Flint, J. and T. Shenk. 1997. Viral transactivating proteins.
Annu. Rev. Genet. 31: 177–212.
Graeber, T.G., J.F. Peterson, M. Tsai, K. Monica, A.J. Fornace,
and A.J. Giaccia. 1994. Hypoxia induces accumulation of
p53 protein, but activation of a G(1)-phase checkpoint by
low-oxygen conditions is independent of p53 status. Mol.
Cell. Biol. 14: 6264–6277.
Greenblatt, M.S., W.P. Bennett, M. Hollstein, and C.C. Harris.
1994. Mutations in the p53 tumor suppressor gene: Clues to
cancer etiology and molecular pathogenesis. Cancer Res.
54: 4855–4878.
Griffiths, S.D., A.R. Clarke, L.E. Healy, G. Ross, A.M. Ford,
M.L. Hooper, A.H. Wyllie, and M. Greaves. 1997. Absence of
p53 permits propagation of mutant cells following genotoxic
damage. Oncogene 14: 523–531.
Haber, D.A. 1997. Splicing into senescence: The curious case of
p16 and p19ARF. Cell 91: 555–558.
Harlow, E., B.R. Franza, Jr., and C. Schley. 1985. Monoclonal
antibodies specific for adenovirus early region 1A proteins:
extensive heterogeneity in early region 1A products. J. Virol.
55: 533–546.
Harper, J.W., G.R. Adami, N. Wei, K. Khandan, and S.J. Elledge.
1993. The p21 cdk-interacting protein Cip1 is a potent in-
hibitor of G1 cyclin-dependent kinases. Cell 75: 805–816.
E1A activates p53 via p19ARF
GENES & DEVELOPMENT 2441
 Cold Spring Harbor Laboratory Press on March 23, 2012 - Published by genesdev.cshlp.orgDownloaded from 
Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 pro-
motes the rapid degradation of p53. Nature 387: 296–299.
Hermeking, H. and D. Eick. 1994. Mediation of c-myc induced
apoptosis by p53. Science 265: 2091–2093.
Jacks, T., L. Remington, B.O. Williams, E.M. Schmitt, S. Hal-
achmi, R.T. Bronson, and R.A. Weinberg. 1994. Tumor spec-
trum analysis in p53-mutant mice. Curr. Biol. 4: 1–7.
Kamijo, T., F. Zindy, M.F. Roussel, D.E. Quelle, J.R. Downing,
R.A. Ashmun, G. Grosveld, and C.J. Sherr. 1997. Tumor sup-
pression at the mouse INK4a locus mediated by the alterna-
tive reading frame product p19ARF. Cell 91: 649–659.
Kamijo, T., J.S. Weber, G. Zambetti, F. Zindy, M.F. Roussel, and
C.J. Sherr. 1998. Interactions of the ARF tumor suppressor
with p53 and Mdm2. Proc. Natl. Acad. Sci. 95: 8292–8297.
Kastan, M.B., O. Onyekwere, D. Sidransky, B. Vogelstein, and
R.W. Craig. 1991. Participation of p53 protein in the cellular
response to DNA damage. Cancer Res. 51: 6304–6311.
Ko, L.J. and C. Prives. 1996. p53: Puzzle and paradigm. Genes &
Dev. 10: 1054–1072.
Kubbutat, M.H., S.N. Jones, and K.H. Vousden. 1997. Regula-
tion of p53 stability by Mdm2. Nature 387: 299–303.
Lane, D.P. and L.V. Crawford. 1979. T antigen is bound to a host
protein in SV40-transformed cells. Nature 278: 261–263.
Levine, A.J. 1997. p53, the cellular gatekeeper for growth and
division. Cell 88: 323–331.
Linke, S.P., K.C. Clarkin, A. Di Leonardo, A. Tsou, and G.M.
Wahl. 1996. A reversible, p53-dependent G0/G1 cell cycle
arrest induced by ribonucleotide depletion in the absence of
detectable DNA damage. Genes & Dev. 10: 934–947.
Linzer, D.I.H. and A.J. Levine. 1979. Characterization of a 54K
dalton cellular SV40 tumor antigen present in SV40 trans-
formed cells and uninfected embryonal carcinoma cells. Cell
17: 43–52.
Livingstone, L.R., A. White, J. Sprouse, E. Livanos, T. Jacks, and
T.D. Tlsty. 1992. Altered cell cycle arrest and gene amplifi-
cation potential accompany loss of wild-type p53. Cell
70: 923–935.
Lowe, S.W. and H.E. Ruley. 1993. Stabilization of the p53 tumor
suppressor is induced by adenovirus E1A and accompanies
apoptosis. Genes & Dev. 7: 535–545.
Lowe, S.W., H.E. Ruley, T. Jacks, and D.E. Housman. 1993.
p53-dependent apoptosis modulates the cytotoxicity of anti-
cancer agents. Cell 74: 954–967.
Lowe, S.W., S. Bodis, A. McClatchey, L. Remington, H.E. Ruley,
D. Fisher, D.E. Housman, and T. Jacks. 1994a. p53 status and
the efficacy of cancer therapy in vivo. Science 266: 807–810.
Lowe, S.W., T. Jacks, D.E. Housman, and H.E. Ruley. 1994b.
Abrogation of oncogene-associated apoptosis allows trans-
formation of p53-deficient cells. Proc. Natl. Acad. Sci.
91: 2026–2030.
Maki, C.G., J.M. Huibregtse, and P.M. Howley. 1996. In vivo
ubiquitination and proteasome-mediated degradation of
p53(1). Cancer Res. 56: 2649–2654.
McCurrach, M.E., T.M. Connor, C.M. Knudson, S.J. Korsmeyer,
and S.W. Lowe. 1997. bax-deficiency promotes drug resis-
tance and oncogenic transformation by attenuating p53-de-
pendent apoptosis. Proc. Natl. Acad. Sci. 94: 2345–2349.
Pomerantz, J., N. Schreiber-Agus, N.J. Liegeois, A. Silverman, L.
Alland, L. Chin, J. Potes, K. Chen, I. Orlow, H.W. Lee, C.
Cordon-Cardo, and R.A. DePinho. 1998. The INK4a tumor
suppressor gene product, p19ARF, interacts with MDM2 and
neutralizes MDM2’s inhibition of p53. Cell 92: 713–723.
Quelle, D.E., F. Zindy, R.A. Ashmun, and C.J. Sherr. 1995. Al-
ternative reading frames of the INK4a tumor suppressor gene
encode two unrelated proteins capable of inducing cell cycle
arrest. Cell 83: 993–1000.
Querido, E., J.G. Teodoro, and P.E. Branton. 1997. Accumula-
tion of p53 induced by the adenovirus E1A protein requires
regions involved in the stimulation of DNA synthesis. J.
Virol. 71: 3526–3533.
Ross, W.E. and M.O. Bradley. 1981. DNA double-stranded
breaks in mammalian cells after exposure to intercalating
agents. Biochim. Biophys. Acta 654: 129–134.
Samuelson, A.V. and S.W. Lowe. 1997. Selective induction of
p53 and chemosensitivity in RB-deficient cells by E1A mu-
tants unable to bind the RB-related proteins. Proc. Natl.
Acad. Sci. 94: 12094–12099.
Serrano, M., G.J. Hannon, and D. Beach. 1993. A new regulatory
motif in cell-cycle control causing specific inhibition of cy-
clin D/CDK4. Nature 366: 704–707.
Serrano, M., A.W. Lin, M.E. McCurrach, D. Beach, and S.W.
Lowe. 1997. Oncogenic ras provokes premature cell senes-
cence associated with accumulation of p53 and p16INK4a.
Cell 88: 593–602.
Shieh, S.Y., M. Ikeda, Y. Taya, and C. Prives. 1997. DNA dam-
age-induced phosphorylation of p53 alleviates inhibition by
MDM2. Cell 91: 325–334.
Siliciano, J.D., C.E. Canman, Y. Taya, K. Sakaguchi, E. Appella,
and M.B. Kastan. 1997. DNA damage induces phosphorylation
of the amino terminus of p53. Genes & Dev. 11: 3471–3481.
Symonds, H., L. Krall, L. Remington, M. Saenzrobles, S. Lowe,
T. Jacks, and T. Vandyke. 1994. p53-dependent apoptosis
suppresses tumor growth and progression in vivo. Cell
78: 703–711.
Wagner, A.J., J.M. Kokontis, and N. Hay. 1994. Myc-mediated
apoptosis requires wild-type p53 in a manner independent of
cell cycle arrest and the ability of p53 to induce p21waf1/
cip1. Genes & Dev. 8: 2817–2830.
Weinberg, R.A. 1995. The retinoblastoma protein and cell cycle
control. Cell 81: 323–330.
Werness, B.A., A.J. Levine, and P.M. Howley. 1990. Association
of human papillomavirus types 16 and 18 E6 proteins with
p53. Science 248: 76–79.
Whyte, P., K.J. Buchkovich, J.M. Horowitz, S.H. Friend, M. Ray-
buck, R.A. Weinberg, and E. Harlow. 1988a. Association be-
tween an oncogene and an anti-oncogene: The adenovirus
E1A proteins bind to the retinoblastoma gene product. Na-
ture 334: 124–129.
Whyte, P., H.E. Ruley, and E. Harlow. 1988b. Two regions of the
adenovirus early region 1A proteins are required for trans-
formation. J. Virol. 62: 257–265.
Whyte, P., N.M. Williamson, and E. Harlow. 1989. Cellular tar-
gets for transformation by the adenovirus E1A proteins. Cell
56: 67–75.
Wu, X., J.H. Bayle, D. Olson, and A.J. Levine. 1993. The p53–
mdm-2 autoregulatory feedback loop. Genes & Dev.
7: 1126–1132.
Xiong, Y., G.J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and
D. Beach. 1993. p21 is a universal inhibitor of cyclin kinases.
Nature 366: 701–705.
Yin, Y., M.A. Tainsky, F.Z. Bischoff, L.C. Strong, and G.M.
Wahl. 1992. Wild-type p53 restores cell cycle control and
inhibits gene amplification in cells with mutant p53 alleles.
Cell 70: 937–948.
Zhang, Y., Y. Xiong, and W.G. Yarbrough. 1998. ARF promotes
MDM2 degradation and stabilizes p53: ARF-INK4a locus de-
letion impairs both the Rb and p53 tumor suppression path-
ways. Cell 92: 725–734.
Zindy, F., C.M. Eischen, D.H. Randle, T. Kamijo, J.L. Cleveland,
C.J. Sherr, and M.F. Roussel. 1998. MYC-induced immortal-
ization and apoptosis targets the ARF-p53 pathway. Genes &
Dev. (this issue).
de Stanchina et al.
2442 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on March 23, 2012 - Published by genesdev.cshlp.orgDownloaded from 
